FDA's Food Advisory Committee will meet June 20-21 to discuss "scientific issues and principles involved in assessing and evaluating whether a 'new' infant formula supports normal physical growth in infants when consumed under its intended conditions of use." Meeting is second in a series to assess infant formula quality issues; first took place April 4-5 (1"The Tan Sheet" April 8, 2002, p. 3). FAC will meet at the Holiday Inn, 1000 Baltimore Ave., College Park, Md. For more information, contact CFSAN's Constance Hardy at (301) 436-1433...

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.